Ghazi-Noori, Ali-Reza
Woodham, Rachel D.
Rezaei, Hakimeh
Sharif, Mhd Saeed
Bramon, Elvira
Ritter, Philipp
Bauer, Michael
Young, Allan H.
Fu, Cynthia H.Y.
Funding for this research was provided by:
Milken Institute (BD-0000000029)
Article History
Received: 28 March 2024
Accepted: 5 August 2024
First Online: 20 August 2024
Declarations
:
: The study was conducted in accordance with the The Code of Ethics of the World Medical Association (Declaration of Helsinki) and approved by the London Fulham Research Ethics Committee (21/LO/0910). All participants provided written informed consent for their participation. The privacy and rights of human subjects was observed at all times.
: Not applicable.
: tDCS devices were provided by Flow Neuroscience. Authors AG, RW, HR, MSS, PR, EB and MB do not report any declarations of interest. CF has received funding from Flow Neuroscience. Author AY reports the following declaration of interests: Paid lectures and advisory boards for the following companies with drugs used in affective and related disorders: Flow Neuroscience, Novartis, Roche, Janssen, Takeda, Noema pharma, Compass, Astrazenaca, Boehringer Ingelheim, Eli Lilly, LivaNova, Lundbeck, Sunovion, Servier, Livanova, Janssen, Allegan, Bionomics, Sumitomo Dainippon Pharma, Sage, Neurocentrx. Principal Investigator for the following studies: (1) the Restore-Life VNS registry study funded by LivaNova; (2) ESKETINTRD3004: “An Open-label, Long-term, Safety and Efficacy Study of Intranasal Esketamine in Treatment-resistant Depression”; (3) The Effects of Psilocybin on Cognitive Function in Healthy Participants; (4) The Safety and Efficacy of Psilocybin in Participants with Treatment-Resistant Depression (P-TRD); (5) A Double-Blind, Randomized, Parallel-Group Study with Quetiapine Extended Release as Comparator to Evaluate the Efficacy and Safety of Seltorexant 20 mg as Adjunctive Therapy to Antidepressants in Adult and Elderly Patients with Major Depressive Disorder with Insomnia Symptoms Who Have Responded Inadequately to Antidepressant Therapy. (Janssen); (6) An Open-label, Long-term, Safety and Efficacy Study of Aticaprant as Adjunctive Therapy in Adult and Elderly Participants with Major Depressive Disorder (MDD). (Janssen); (7) A Randomized, Double-blind, Multicentre, Parallel-group, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Aticaprant 10 mg as Adjunctive Therapy in Adult Participants with Major Depressive Disorder (MDD) with Moderate-to-severe Anhedonia and Inadequate Response to Current Antidepressant Therapy; (8) A Study of Disease Characteristics and Real-life Standard of Care Effectiveness in Patients with Major Depressive Disorder (MDD) With Anhedonia and Inadequate Response to Current Antidepressant Therapy Including an SSRI or SNR. (Janssen). UK Chief Investigator for the following studies: (1) Novartis MDD study MIJ821A12201; (2) Compass; COMP006 & COMP007 studies. Grant funding (past and present): NIMH (USA); CIHR (Canada); NARSAD (USA); Stanley Medical Research Institute (USA); MRC (UK); Wellcome Trust (UK); Royal College of Physicians (Edin); BMA (UK); UBC-VGH Foundation (Canada); WEDC (Canada); CCS Depression Research Fund (Canada); MSFHR (Canada); NIHR (UK). Janssen (UK) EU Horizon 2020. Editor of Journal of Psychopharmacology and Deputy Editor, BJPsych Open. No shareholdings in pharmaceutical companies.